AU2015342813B2 - Methods to target transcriptional control at super-enhancer regions - Google Patents

Methods to target transcriptional control at super-enhancer regions Download PDF

Info

Publication number
AU2015342813B2
AU2015342813B2 AU2015342813A AU2015342813A AU2015342813B2 AU 2015342813 B2 AU2015342813 B2 AU 2015342813B2 AU 2015342813 A AU2015342813 A AU 2015342813A AU 2015342813 A AU2015342813 A AU 2015342813A AU 2015342813 B2 AU2015342813 B2 AU 2015342813B2
Authority
AU
Australia
Prior art keywords
inhibitor
alvocidib
cdk9
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015342813A
Other languages
English (en)
Other versions
AU2015342813A1 (en
Inventor
David J. Bearss
Steven L. Warner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Oncology Inc
Original Assignee
Sumitomo Pharma Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Oncology Inc filed Critical Sumitomo Pharma Oncology Inc
Publication of AU2015342813A1 publication Critical patent/AU2015342813A1/en
Assigned to SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. reassignment SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. Request for Assignment Assignors: TOLERO PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2015342813B2 publication Critical patent/AU2015342813B2/en
Assigned to SUMITOMO PHARMA ONCOLOGY, INC. reassignment SUMITOMO PHARMA ONCOLOGY, INC. Request to Amend Deed and Register Assignors: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015342813A 2014-11-07 2015-11-06 Methods to target transcriptional control at super-enhancer regions Ceased AU2015342813B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462077042P 2014-11-07 2014-11-07
US62/077,042 2014-11-07
US201562150110P 2015-04-20 2015-04-20
US62/150,110 2015-04-20
PCT/US2015/059566 WO2016073913A1 (en) 2014-11-07 2015-11-06 Methods to target transcriptional control at super-enhancer regions

Publications (2)

Publication Number Publication Date
AU2015342813A1 AU2015342813A1 (en) 2017-05-18
AU2015342813B2 true AU2015342813B2 (en) 2021-04-22

Family

ID=55909897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015342813A Ceased AU2015342813B2 (en) 2014-11-07 2015-11-06 Methods to target transcriptional control at super-enhancer regions

Country Status (12)

Country Link
US (2) US20180280407A1 (OSRAM)
EP (1) EP3215135B1 (OSRAM)
JP (1) JP6689841B2 (OSRAM)
KR (1) KR20170092543A (OSRAM)
CN (1) CN107205959B (OSRAM)
AU (1) AU2015342813B2 (OSRAM)
BR (1) BR112017009552A8 (OSRAM)
CA (1) CA2965690A1 (OSRAM)
IL (1) IL251816B (OSRAM)
MX (1) MX385762B (OSRAM)
RU (1) RU2737508C2 (OSRAM)
WO (1) WO2016073913A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6851978B2 (ja) 2015-04-20 2021-03-31 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ミトコンドリアプロファイリングによるアルボシジブ応答の予測
JP6510075B2 (ja) 2015-05-18 2019-05-08 トレロ ファーマシューティカルズ， インコーポレイテッド バイオアベイラビリティが高いアルボシジブプロドラッグ
EP3331510A4 (en) 2015-08-03 2019-04-03 Tolero Pharmaceuticals, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
WO2019113260A1 (en) * 2017-12-05 2019-06-13 The Regents Of The University Of Colorado A Body Corporate Genomic targets of histone deacetylase inhibitors (hdaci) and methods of use thereof
EP3758753A1 (en) * 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
CA3115315A1 (en) 2018-10-15 2020-04-23 Anthony A. HYMAN Compounds for treatment of diseases and methods of screening therefor
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020163795A1 (en) 2019-02-08 2020-08-13 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CA3153010A1 (en) 2019-09-18 2021-03-25 Dewpoint Therapeutics, Inc. Methods of screening for condensate-associated specificity and uses thereof
EP4453261A1 (en) * 2021-12-22 2024-10-30 Cornell University Prognostic/predictive epigenetic breast cancer signature

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028001A2 (en) * 2001-09-24 2003-04-03 Lg Life Sciences Ltd. Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol
US20140303167A1 (en) * 2011-08-22 2014-10-09 Lead Discovery Center Gmbh Cdk9 inhibitors in the treatment of midline carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
RU2016122654A (ru) * 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
CA3000633C (en) * 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028001A2 (en) * 2001-09-24 2003-04-03 Lg Life Sciences Ltd. Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol
US20140303167A1 (en) * 2011-08-22 2014-10-09 Lead Discovery Center Gmbh Cdk9 inhibitors in the treatment of midline carcinoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FISKUS et al., "Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells", Small Molecule Therapeutics, (2014-01-16), vol. 13, no. 5, pp. 1142 - 1154 *
Tomoaki Fukui ET AL, "The Analysis of the Effect of JQ1 and Flavopiridol on Chondrocytes under Inflammatory Stimuli", ORS 2014 Annual Meeting, (2014-03-15), URL: http://www.ors.org/Transactions/60/1251.pdf, (2016-05-26) *

Also Published As

Publication number Publication date
US20200316084A1 (en) 2020-10-08
BR112017009552A2 (pt) 2018-01-02
AU2015342813A1 (en) 2017-05-18
IL251816B (en) 2022-03-01
CN107205959B (zh) 2021-02-12
WO2016073913A1 (en) 2016-05-12
RU2737508C2 (ru) 2020-12-01
JP6689841B2 (ja) 2020-04-28
JP2017533222A (ja) 2017-11-09
CA2965690A1 (en) 2016-05-12
EP3215135B1 (en) 2020-05-13
KR20170092543A (ko) 2017-08-11
EP3215135A4 (en) 2018-05-16
IL251816A0 (en) 2017-06-29
RU2017118833A (ru) 2018-12-10
RU2017118833A3 (OSRAM) 2019-06-17
US20180280407A1 (en) 2018-10-04
MX2017005861A (es) 2017-06-26
EP3215135A1 (en) 2017-09-13
MX385762B (es) 2025-03-18
CN107205959A (zh) 2017-09-26
BR112017009552A8 (pt) 2022-10-18

Similar Documents

Publication Publication Date Title
AU2015342813B2 (en) Methods to target transcriptional control at super-enhancer regions
US10835537B2 (en) Combination therapies for treatment of cancer
EP2785349B2 (en) Combination treatment of cancer
EP3191513B1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
JP6619361B2 (ja) ＩｇＡ腎症を治療するためのジンセノサイドＭ１の使用
KR20180094989A (ko) 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법
JP2020534299A5 (OSRAM)
US11524055B2 (en) Methods for treating diseases mediated by ERBB4-positive pro-inflammatory macrophages
EP4048284B1 (en) Method for treating cancers
EP3028704B1 (en) Combinations of methotrexate and simvastatin for use in the treatment of osteosarcoma
CN115038447A (zh) 用于治疗癌症的组合疗法
HK1242968A1 (en) Methods to target transcriptional control at super-enhancer regions
HK1242968B (en) Methods to target transcriptional control at super-enhancer regions
CN110494137B (zh) 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途
Cui et al. Methylene blue exerts anticonvulsant and neuroprotective effects on self-sustaining status epilepticus (SSSE) induced by prolonged basolateral amygdala stimulation in Wistar rats
CN117018202A (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
Ismail et al. Clinical outcome and toxicity in post-COVID suspected cases of mucormycosis treated with amphotericin B at dedicated COVID hospital: a prospective observational study.
TW201513871A (zh) 用於癌症治療之抗群集素（ｃｌｕｓｔｅｒｉｎ）單一療法
CN117427079A (zh) 含氰基取代的大环类化合物的用途
Shaw et al. Survival Time is Problematic as an Indicator of an anti-AML Drug’s Effectiveness
Santos-Moreno et al. OP0148 Effectiveness of Conventional DMARDS Using A Treat to Target Strategy in the Context of A Large Cohort of Rheumatoid Arthritis Patients
HK1241390B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.

Free format text: FORMER APPLICANT(S): TOLERO PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SUMITOMO PHARMA ONCOLOGY, INC.

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired